ACTINEER
LIVE

Serial Number

79397582

Owner

ITM Isotope Technologies Munich SE

Attorney

Kari Moyer-Henry

Filing Date

Feb 8, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ACTINEER Trademark

Serial Number: 79397582 • Registration: 7741628

ACTINEER is a trademark filed by ITM Isotope Technologies Munich SE on February 8, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

ITM Isotope Technologies Munich SE (15 trademarks)

Lichtenbergstr. 1

Entity Type: 03

Trademark Details

Filing Date

February 8, 2024

Registration Date

April 1, 2025

Published for Opposition

February 11, 2025

Goods & Services

Medical instruments, apparatus and containers for the production of radiopharmaceutical preparations, namely sample preparation devices automatically or manually operated in particular for the production of actinium-225 in GMP quality; medical instruments, apparatus and containers for the production of radiopharmaceutical preparations, namely sample preparation devices automatically or manually operated in particular for the production of bismuth-213 in GMP quality; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers, in particular devices containing fluidic processing components as valves, small vessels (5-500 ml) and purification columns for the production of a radiotherapeutic or radiodiagnostic substance, in particular for the production of actinium-225 in GMP quality; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular devices containing fluidic processing components as valves, small vessels (5-500 ml) and purification columns for the production of a radiotherapeutic or radiodiagnostic substance, in particular for the production of bismuth-213 in GMP quality; radionuclide generator for radiopharmaceutical purpose

Radiopharmaceutical diagnostic preparations for medical purposes; radiopharmaceutical diagnostic preparations for pharmaceutical purposes; radiopharmaceutical therapeutic preparations for medical purposes; radiopharmaceutical therapeutic preparations for pharmaceutical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy, positron emission tomography, single photon emission computed tomography, target radionuclide therapy and peptide receptor radionuclide therapy; radiopharmaceutical preparations, in particular actinium-containing radiopharmaceutical products in GMP quality; radiopharmaceutical preparations, in particular bismuth-containing radiopharmaceutical products in GMP quality; radiopharmaceutical preparations for use in oncology, in particular radiopharmaceuticals containing radioisotopes, in particular actinium-225; radiopharmaceutical preparations for use in oncology, in particular radiopharmaceuticals containing radioisotopes, in particular bismuth-213; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular actinium-225 for the treatment of tumour diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular bismuth-213 for the treatment of tumour diseases; target radiopharmaceuticals containing a target molecule, in particular peptide , depending on the indication, and a medical radioactive isotope; target radiopharmaceuticals containing a target molecule, in particular an antibody depending, on the indication, and a medical radioactive isotope; radiopharmaceuticals containing actinium-225 and its complexes; radiopharmaceuticals containing bismuth-213 and its complexes

Chemical substances, chemical materials and chemical preparations for use in the manufacture of medical products; chemical substances, chemical materials and chemical preparations for use in the manufacture of radiopharmaceutical products; chemical raw materials, in particular actinium-225 radiochemical, for the formulation of radiopharmaceutical products; chemical raw materials, in particular bismuth-213, for the formulation of radiopharmaceutical products

Medical services, in particular medical services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology, nuclear medicine and brachytherapies, namely intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and radionuclide therapy, peptide receptor radionuclide therapy, personal nuclear medicine and precision oncology; medical services for theranostics in the field of precision oncology

Scientific and technological services and research relating to the use of actinium-225, in particular medical and pharmacological research services relating to the use of actinium-225; scientific and technological services and research relating to the use of bismuth-213, in particular medical and pharmacological research services relating to the use of bismuth-213; scientific and technological services and research relating to the use of other alpha emitters, in particular medical and pharmacological research services relating to the use of other alpha emitters

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 30, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 12, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Nov 12, 2025 OPNR
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 31, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 15, 2025 FICS
FINAL DISPOSITION PROCESSED
Oct 14, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 2, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 1, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 1, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 11, 2025 NPUB
PUBLISHED FOR OPPOSITION
Feb 11, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 5, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 21, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 30, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 30, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 30, 2024 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 18, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 18, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 18, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 18, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 18, 2024 COAR
REFUSAL PROCESSED BY IB
Sep 30, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 11, 2024 RFCS
REFUSAL PROCESSED BY MPU
Sep 11, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 9, 2024 RFCR
NON-FINAL ACTION WRITTEN
Sep 8, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 2, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 20, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 20, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 13, 2024 REPR